Meibomian gland dysfunction(MGD)is a chronic, diffuse disorder of the meibomian glands characterized by obstruction of the terminal ducts of the meibomian glands and/or qualitative and/or quantitative abnormalities in glandular secretion. It can lead to tear film changes, symptoms of recurrent eye irritation and/or foreign body sensation, and in severe cases, vision loss, which greatly affects the quality of life and daily work of patients. Although, there are various traditional protocols for the clinical treatment of MGD, which are classified as artificial tears, hot compresses on the eyelids, blepharoplasty massage, and eyelid cleansing, etc., the limitations of traditional treatment protocols that require repetitive manipulation, the tendency for ocular discomfort to recur in some patients after treatment, and the possibility of symptom exacerbation in a few patients have greatly decreased patient compliance, coupled with the fact that there is no unified guideline standard for treatment protocols regarding MGD both at home and abroad at this point in time. Therefore, the disease faces severe challenges in clinical treatment. In recent years, with the deepening of the understanding of the pathogenesis of MGD and research, certain breakthroughs have been made in the field of MGD treatment, and emerging therapeutic approaches have emerged and gradually gained attention and importance. The purpose of this review is to summarize the current progress of emerging MGD treatment and provide reference for the clinical treatment of MGD.